FDA Guidance :Contract Manufacturing Arrangements for Drugs: Quality Agreements

Last year, FDA published its draft guidance, officially titled “Contract Manufacturing Arrangements for Drugs: Quality Agreements”. Here are some of the highlights.

First, a Quality Agreement between a Sponsor and Contract Manufacturer has never been, nor is it now, explicitly required by FDA regulations. However, responsibilities and procedures of the each company’s respective Quality Units are required to be documented, so a Quality Agreement that outlines the responsibilities of each company is a logical next step. Note that “Contract Manufacturer” refers to any Contracted Facility that provides some or all manufacturing services, including processing, packing, labeling, holding, or testing.

In Europe, Sponsors (or, in the vernacular of the draft guidance, “Owners”) can outsource the final product release/rejection of finished goods for distribution. In the US, sponsors always assume this responsibility and cannot delegate or outsource it.

Because Contracted Facilities often provide services to multiple Sponsors, FDA advises that special consideration be given to reporting information about objectionable conditions.  Sponsors may wish to require that their Contracted Facilities make them aware of manufacturing deficiencies that may impact their products, even if the deficiencies were observed during an inspection of another Sponsor’s product.  (Note, our consultants also suggest that the Quality Agreement require that a Contracted Facility notify its Sponsor whenever the FDA inspects the facility.  The name of the inspected product and its Sponsor would be kept confidential, but this reporting of inspections tells a Sponsor how often FDA visits the site.)

FDA acknowledges that processes can change at both Sponsor and Contracted Facility companies for a variety of legitimate reasons, so communicating changes between the two companies should be discussed in the Quality Agreement. Examples include additional products brought into the line/facility, changes to key personnel and suppliers, and changes resulting from stability studies, process improvement projects, investigations into manufacturing deviations, out-of-specification results, customer complaints, recalls, or adverse event reports.

Finally, a Quality Agreement does not exempt Contracted Facilities from CGMP compliance. Regardless of the allocation of responsibilities in the Quality Agreement, the Contracted Facility cannot essentially agree to manufacture under non-CGMP conditions. Both companies could be held responsible – the Contract Manufacturer for the non-compliance, and the Sponsor for lack of oversight. FDA provided a few examples:
The Contracted Facility receives a Warning Letter for deficient maintenance of facilities and equipment. The Quality Agreement specifies the Sponsor is responsible for this, yet the Owner has failed to provide the requisite resources or carry out the necessary upgrades and maintenance, and the Contracted Facility has continued to operate under non-CGMP conditions. (Possible course of action: the Contracted Facility could bear the costs of modifying operations in order to maintain CGMP compliance, and then seek redress from the Sponsor later.)

Batch records do not match the manufacturing process of adding reclaimed powder, but the Contracted Facility claims that this is just as the Sponsor specified. (Possible course of action: the Contracted Facility could refuse to carry out the additional manufacturing step without including it in the batch record).
The draft guidance concludes by noting that “Owners and Contracted Facilities can draw on quality management principles to carry out the complicated process of contract drug manufacturing by defining, establishing, and documenting the responsibilities of all parties involved in drug manufacturing, testing, or other support operations.”

By Laurie Meehan, Polaris Compliance Consultants, Inc.

Categories of Bio-Medical Waste


---------------------------------------------------------------------------------
Option         Waste Category                     Treatment & Disposal                                                                                 
--------------------------------------------------------------------------------
Category No. I Human Anatomical Waste
               (human tissues, organs, body parts) incineration@/deep burial*

Category No. 2 Animal Waste
               (animal tissues, organs, body parts carcasses, bleeding parts, fluid,         incineration@/deep burial*
               blood and experimental animals used in research, waste generated
               by veterinary hospitals colleges, discharge from hospitals, animal
               houses)

Category No 3 Microbiology & Biotechnology Waste
               (wastes from laboratory cultures, stocks or specimens of micro-                  local autoclaving/micro-organisms live or attenuated vaccines,                    human and animal cell waving/incineration@culture used in research                and infectious agents from research and industrial laboratories,                  wastes from production of biologicals,toxins, dishes and devices                  used for transfer of cultures)

Category No 4  Waste sharps
               (needles, syringes, scalpels, blades, glass, etc. that may cause                  disinfection (chemical treat-puncture and cuts. This includes both                used and unused sharps)ment@01/auto claving/micro-                                waving and mutilation/shredding"

Category No 5 Discarded Medicines and Cytotoxic drugs
               (wastes comprising of outdated, contaminated and discarded                         inc ineratio n@/destruct ion and medicines)drugs disposal in                     secured landfills

Category No 6  Solid Waste
               (Items contaminated with blood, and body fluids including cotton,
               dressings, soiled plaster casts, lines, beddings, other material        incineration@
               contaminated with blood)                                             autoclaving/microwaving

Category No. 7 Solid Waste
               (wastes generated from disposable items other than the waste                       shaprs disinfection by chemical such as tubings, catheters,                       intravenous sets etc). treatment@@ autoclaving/                                  microwaving and mutilation/shredding##

Category No. 8 Liquid Waste
                (waste generated from laboratory and washing, cleaning, house-                    disinfection by chemical keeping and disinfecting                                ctivities) treatment@@ and discharge into drains.

Category No. 9 Incineration Ash
               (ash from incineration of any bio-medical waste)                                   disposal in municipal landfill

Category No. 10 Chemical Waste
               (chemicals used in production of biologicals, chemicals used in                   chemical treatment@@ and disinfection, as insecticides,                           etc.)discharge into drains for liquids and secured landfill for                    solids
---------------------------------------------------------------------------------

@@ Chemicals treatment using at least 1% hypochlorite solution or any other equivalent chemical reagent. It must be ensured that chemical treatment ensures disinfection.

## Multilation/shredding must be such so as to prevent unauthorised reuse.

@ There will be no chemical pretreatment before incineration. Chlorinated plastics shall not be incinerated.
* Deep burial shall be an option available only in towns with population less than five lakhs and in rural areas.

SCHEDULE II
(see Rule 6)
COLOUR CODING AND TYPE OF CONTAINER FOR DISPOSAL OF BIO-MEDICAL WASTES
Colour Conding
Type of Container -I Waste Category
Treatment options as per
Schedule I
Yellow
Plastic bag Cat. 1, Cat. 2, and Cat. 3,
Cat. 6.
Incineration/deep burial

Red
Disinfected container/plastic bag Cat. 3, Cat. 6, Cat.7.
Autoclaving/Microwaving/
Chemical Treatment
Blue/White
translucent
Plastic bag/puncture proof Cat. 4, Cat. 7.
Container
Autoclaving/Microwaving/
Chemical Treatment and
destruction/shredding
Black
Plastic bag Cat. 5 and Cat. 9 and
Cat. 10. (solid)
Disposal in secured landfill

Big Data Meets Measurement in Manufacturing



Big Data headlines not only tech news but also popular news—as in what’s the government doing with all the information it’s storing about us. Big Data comprises just a twig compared with the fullgrown oak that Big Analog Data can generate. National Instruments Fellow Tom Bradicich mentioned twice in separate interviews during NIWeek last month that all of the analog data acquired from manufacturing and products—a.k.a. the Internet of Things (IoT)—dwarfs what is currently known as Big Data.

Keep Your Document Control System in Control

Document control is always an interesting topic for discussion.  It seems like a simple topic and area for compliance, but I often run into companies with document control systems that are overly complicated and difficult to manage.  Many companies separate document control for quality system procedures/processes from other types of change control.  In reality, document control is one element of the overall change control and records management requirements.  There are many procedures, formats, tools, and/or styles for managing quality documents and records.   Let’s take a look at how these key activities are related and why we should focus on implementation of strong change control processes within the quality systems — rather than just a document control process.

As you look at the various regulations and/or standards like 21 cfr (210, 211, 820, 600, etc.), ISO (9001, 13485, etc.), EU, JPAL, etc., they all require document and change control/management.  Additionally, 21 cfr 11 describes the FDA requirements for the use and management of electronic records.

We are all familiar with the standard document control pyramid. The diagram below reminds us of the relationship between documents and records within the Quality Management System.



You can see from this diagram that there are many types of Quality System documents you could generate.  I strongly recommend that you “right size” your procedures and records to assure compliance and simplicity for the organization. 

  • Determine the relationship between the various documents and which ones meet the needs of your specific business. 
  • The regulations/standards identify the minimal procedures that are actually required to meet the defined requirements. 
The following list was extracted from the ISO 13485 standard
  • 4.2.3 Control of documents
  • 4.2.4 Control of records
  • 6.4 Work environment
  • 7.3.1 Design and development planning
  • 7.4.1 Purchasing process
  • 7.5.1.2.3 Servicing activities
  • 7.5.2.1 Validation of processes for production and service provision —
  • General requirements
  • 7.5.2.2 Particular requirements for sterile medical devices
  • 7.5.3.1 Identification and traceability — Identification
  • 7.5.3.2.1 Identification and traceability — Traceability
  • 7.5.5 Preservation of product
  • 7.6 Control of monitoring and measuring devices
  • 8.2.1 Monitoring and measurement — Feedback
  • 8.2.2 Internal audit
  • 8.3 Control of nonconforming product
  • 8.4 Analysis of data
  • 8.5.1 Improvement — General
  • 8.5.2 Corrective action
  • 8.5.3 Preventive action

  • You do not need a work instruction/procedure for every activity in your operation.  Create these additional documents if they help the employees perform the operations/tasks or assure higher level of quality.   
  • Keep it simple.

There is specific information that should be addressed as you implement the document/record/change control system:

  1. Document identification/number system – develop a simple but intelligent number system.  I have seen everything from basic sequential numbering (1, 2,3,etc.) to extremely long alpha/digit numbers with built in intelligence.  I recommend something that is meaningful and simple for the employees to understand and find documents.

  • Revision control – identify how the employee knows they are using the correct version of the SOP.  There are many approaches including, but not limited to, alpha characters, numbers, and date codes, to name a few.
  • Purpose – why are you generating the procedure? If you can’t explain why you are writing the document in a couple of sentences, maybe you should think about whether or not it is really needed. 
  • Scope – what/who is impacted by this procedure.  There are times a procedure is not applicable to all functions/sites.  This is a great time to identify what is or isn’t included in the scope of the process.
  • Definitions – this is really a tricky area.  I prefer a stand-alone glossary of terms, rather than building them into the procedure.  Putting all definitions/terms into a glossary document assures consistency in how terms are used.
  • Roles and responsibilities – You may choose to use the RACI (Responsible, Accountable, Consult, Inform) model to identify what roles different functions have in the process. Another option is to call out cross functional  and or interrelationship responsibilities.
  • Records – it is always good practice to identify the records generated as a result of the procedure. 
  • Procedure – this is the actual process being documented.  There are many forms/formats for writing the procedures.  A process flow diagram may work and be more effective than a 14-page document.  Select the format that best meets the process and is easy to demonstrate compliance.

Procedures and records can usually be distributed into three major buckets:

  • Product – those documents that support the design and development of products.  These records make up the Design History File (DHF) and serve as the master record for how the product was designed.
  • Process – those documents that support the manufacturing, procurement, and/or operations of the organization.  These records make up the Device Master Record (DMR) and serve as the master record/recipe for how a particular product is manufactured.
  • Quality System – these documents define the activities and processes necessary to support the quality system requirements. These procedures do not normally impact product design or manufacturing operations.

Implementing an effective document/record control system requires a simple change control process. The FDA is taking a much closer look at planned changes in relation to product and process design.  Unplanned changes are normally documented as deviations and should be included in the evaluation of nonconformances, as a feeder to the CAPA systems.    

There is no requirement to have a separate change control system for each type of document.  One simple process can be established to support all types of changes.  Evaluation of changes should use a risk approach based on major/minor types of change.  The risk based definitions must be included in your procedures and should be determined on specific business needs.  Administrative changes (typo, wording clarification, page numbers etc.) must be addressed but do not require the same level of scrutiny or evaluation.  A good rule of thumb to use when evaluating change is the impact of the change on the form, fit, or function of the product/activity. 

I have seen change processes implemented in many different ways.  I recommend one basic process to address all types of change, rather than individual change processes.  You can develop one process flow and form to support all areas of the quality system.  The following table gives you an example of how you might establish a risk based approach to change control with one process:

Change Control

Product
Process
Quality System
Administrative
Requirements
X
X
NA
NA
Risk Assessment
X
X
NA
NA
Product Verification
X
X
NA
NA
Product Validation
X
X
NA
NA
Training
X
X
X
NA
Process validation
X
X
X
NA
Process Risk Assessment
X
X
X
NA


There are several very effective automated tools on the market that could be considered to support the document/record/change control processes.  The key is to have thought through how you want the processes to work, map out a plan for implementation, validate that the tool meets your business needs and requirements, educate the organization on how the system works and why key decisions were made.

I strongly recommend defining user needs and requirements for the document/record/change control electronic tool prior to purchasing.  Having a defined procedure and process will facilitate the selection activity.  Identify those functions/features the system MUST have versus those that would be NICE to have.  Build a table of these requirements and ask the various suppliers to address your needs.  Each system/tool will have key features and benefits  Knowing what your business needs and wants before making the selection will make the implementation much more effective.

In summary,
  • Document/record control is one of the main cornerstones for a successful quality management system.
  • It is critical that you establish the document/record/change process and controls as simply and clearly as possible.  Make it easy for the employees to understand and use.
  • Change control should be simple and risk based.
  • Automation is great – as long as you are clear about what you are automating and how it needs to work for your business.

Validation Strategies For Nonsterile Solid Dosage Forms

Process qualification, which includes pharmaceutical drug products at a stage prior to commercialization or prior to submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA).  In this stage, it must be demonstrated that the process for manufacture of a drug product is consistent and can produce drug products that are compliant with the Food and Drug Administration’s requirements for filing. 

This stage includes two elements.  The first element focuses on facility design and equipment installation and maintenance while the second includes process performance qualification (PPQ).  Some prerequisites to facility design and equipment installation and maintenance includes validation and qualification of analytical methods, approved standard operating procedures (SOPs) for process validation, implementation of preventive maintenance program (PMs), cleaning validation of equipment, and process specific GMP training.  In structuring a PPQ, CPPs and CQAs must be defined, justified, and documented.  Other process performance qualification activities must be controlled by an approved protocol that includes the scope, strategy, testing, sampling plan, and acceptance criteria. This study is conducted at a manufacturing site, according to a site validation master plan.  Additional strategies are explored below.

Process Qualification Study Strategies:

A strategy needs to be developed for every qualification study and it must be based on deep process understanding gained from the manufacturing experience. Some elements to consider include:

1. Number of Batches: The protocol should include three consecutive batches, with the results summarized in the final process qualification report.

2. Material Selection:  Selection of more than one lot of API and critical raw materials should be used during process qualification (especially if the API or critical raw materials are not dissolved or distributed in solution). Based on the selection of these materials, a process should be designed to validate the robustness of the process.

3. Equipment Selection: The process must be qualified on all equipment intended to be used in the manufacture of the product. For equipment determined as being equivalent, qualification on one piece of equipment is sufficient.

4. Design Space/Parameters Ranges:  For products that have an established design space, the process qualification should be executed at specified conditions within the design space. For conditions that are high risk, high and low parameter ranges should be considered for the process qualification.

5. Process Re-qualification:  Process re-qualification may be required if, for example, a significant deviation from desired process performance is uncovered through stage 3 continued process verification.  The process re-qualification studies should bridge back to the original or pivotal clinical biobatch.

Process Qualification Testing:

Process qualification testing should be based on the established CPPs and CQAs and the control strategy and risk assessments, which characterize the product quality and process consistency.

CPP Monitoring:  Defined critical process parameters should be monitored and reported in the final qualification report.

  • For processes that have a processing fluid (e.g., granulation), microbial testing and hold times will need to be established. For processes where critical ingredients are added as a part of the processing fluid, testing related to the critical ingredient (e.g., assay) at make-up and at the end of hold time should be considered.  
  • For processes involving lubricated granulation, blend uniformity testing must verify that the active ingredient has been distributed throughout the blended bulk uniformly. To determine unit-dose equivalent (1-3x) blend uniformity of the active ingredient on the final, blend samples should taken from the blender. For combination products, all APIs need to be tested for blend uniformity while respective blenders need to be tested for bilayer tablets.
  • For the manufacture of compressed tablets or capsules, during the compression operation a sampling plan should be adopted with around ten evenly spaced intervals throughout the batch processing. After the compression machine is set-up, location one should include the first salable dosage units and location ten should contain the last salable dosage units while location two through nine should be evenly spaced across the lot.  For a process using a double sided machine, both the sides of the machine should be sampled at each location. For the manufacture of combination or bilayer tablets, ample samples should be obtained to properly evaluate all API specific tests.  Specific to bilayer tablets, samples should be taken to evaluate both layers.
  • For the manufacture of film coated tablets, random location sampling should be taken of representative samples. For application of functional membranes, testing should be performed on samples taken from each film coating pan load. For nonfunctional coats, samples may be divided among the film coating pan load.

Acceptance Criteria:

The manufacture process must be validated and reported within the regulatory filing, batch records and final validation report, including all the appropriate specification and procedures (e.g., selected CPPs and release requirements). Any deviation must be investigated and addressed in the validation report. 

Each of the processing steps can be analyzed by evaluating the process control charts (based on three sigma limits) and the historical process capability charts.  These charts should be evaluated for nonrandom systematic behavior.  Ultimately, for all initial process qualification, a comparison must be made to the dissolution profile performed on the biobatch or pivotal reference batch.  A batch may be excluded if a nonprocess related assignable cause, like mechanical failure, has been identified.

Statistical Analysis:

Intra-batch and inter-batch variability should be examined from data collected during process qualification through the analysis of process control charts and process capability charts.

Once a product has completed performance qualification, process validation continues through implementation of continued process verification.  This verification includes monitoring operating procedures, preventive maintenance and calibration programs, deviation investigations, annual review, and change control procedures. Any changes to the process must be evaluated through the process change request system and procedures for process change control to determine the impact to on-going process validation.  A list of intermediate tests for nonsterile solid dosage forms (tablets and capsules) are compiled in Table 1.

Stage 2 process qualification is conducted at the manufacturing site, which is usually a far distance away from product development/process development facilities. Therefore, another important piece of the process validation includes technology transfer to manufacturing facilities. Technology transfer includes detailed process fit, manufacturing readiness, and an execution phase. Process qualification falls under the execution phase.

Continued Process Verification (Stage 3)

The goal of continued process verification (CPV) is “continual assurance that the process remains in a state of control (validated state) during commercial manufacture.”[5] Once a process has gone through process qualification, an ongoing program to collect and analyze product and process data that relate to product quality is necessary. The objective of the on-going process verification program is to understand the sources of variation, its impact on the process and product attributes, and finally to devise a way to control the variation. The knowledge gained through stage 3 of continued process verification provides ongoing assurance that a product remains in a state of control.

In summary, QbD is not a mandated requirement, however, any pharmaceutical company that instills the QbD approach in their DNA of product development (process design, process qualification, and continued process verification) will come out ahead in their value curve, since we live in an increasingly science-driven regulatory environment in 21st century — where compliance and quality have been essential elements of competitiveness and quality drug products. Hopefully these tips and strategies will support you in designing and validating a quality manufacturing process.




A Step-by-Step Guide to Implement Track and Trace

With every recurrence of confirmed counterfeit drug product in the pharmaceutical supply chain, the pressure increases to establish a national standard for pharmaceutical track-and-trace solutions. Although a universal standard has yet to emerge, there is one set of requirements that is currently driving action: the California Board of Pharmacy’s ePedigree.

Moreover, with considerable attention from legislators, regulators, and standards organizations to track and trace a pharmaceutical product throughout its lifecycle, drug manufacturers and packagers are under increased pressure to implement serialization to provide supply-chain integrity to the public.

However, with the deadlines for the California Board of Pharmacy’s ePedigree law quickly approaching, it will be vital for the industry to accelerate its efforts to start putting compliance measures in place in 2013.

With the accelerated pace of regulatory involvement worldwide in serialization and track and trace, a strong working foundation of imminent requirements is necessary.

Several of the U.S. states are in the process of creating legislation for ePedigree; however, California is, by far, drawing the most attention for two reasons:

  1. Although it has pushed the initial enforcement date out, there seems to be a common understanding that the current initial enforcement date of January 1, 2015, will stand.
  2. Of those states actively pursuing similar legislation, California’s requirements are the most demanding. For example, Florida’s law requires the tracking of product to the lot level, whereas California’s goes to the smallest saleable unit level.


California’s legislation is written such that it will effectively be usurped by federal legislation, but it is not known when the feds may introduce similar or overriding legislation. The bottom line? The deadline is fast approaching, and action needs to be taken now in order to comply with the impending law. As you contemplate your track-and-trace efforts or are putting systems in place, you should first keep the following considerations in mind.

Compliance Matters:

Any and all systems added or maintained to resolve the ePedigree initiative must be compliant with the regulations. Although the need to attack the problem of counterfeit medicines in the supply chain is obvious, many of the system design considerations may be derived from an analysis of the regulations the system(s) will address. The following are regulations to keep in mind to help guide your process:

  1. ISO Requirements: Depending on the extent to which a company implements serialization for a packaging operation, there will be significant regulatory impact to a serialization project. At a minimum, there are ISO requirements for a formalized computer-system life-cycle management process. In any case, the use of best practices in today’s world for well-tested and documented business-critical systems is a safe assumption.
  2. CFR Part 11: Other regulations may also be impactful. In the case of pharmaceuticals, 21 CFR Part 11, Electronic Records; Electronic Signatures, there are many requirements that must be met. These include specific actions to ensure authenticity, integrity, and confidentiality of e-records where appropriate.
  3. GAMP 5: The pharmaceutical industry adheres to industry standards that can be found in a document published by the International Society of Pharmaceutical Engineers (ISPE) in its most recent guide, GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems. Immediately upon the formalization of a systematic serialization approach within an organization, the resulting project then becomes subject to standard Good Manufacturing Practices (GMP) Quality Management System requirements. GAMP 5 will drive the project planning and implementation of a structured track-and-trace program in the typical pharmaceutical company.


Within GAMP 5, topics include how:

  • the system will be designed, built, and tested
  • the system will be documented
  • the system will be handed over to the users
  • incidents will be documented, and corrective and preventive measures will be captured and coordinated
  • system changes will be managed
  • system audits will be conducted
  • electronic records will be maintained, retrieved, and archived
  • ... and more

Ask The Right Questions To Form Your Strategy:

Apply a structured analysis of the integrated automation system to assure adequate understanding of the processes and scope of the effort (i.e. determine what business processes, system interfaces, and human control activities need to be assessed) prior to formal project Scope Statement.

Questions to be addressed for this phase should include the following:

  • Is this a global project? If so, what communication and collaboration tools will be used to support the project?
  • What is planned for a proof-of-concept?
  • Which lines will be upgraded?
  • Are multiple facilities involved?
  • Is there a serialization system already in place? If so, has a gap analysis been performed to identify the differences between the “as-is” and the “to-be” processes?
  • Have all important stakeholders been included?
  • How will we be able to insure a good level of communication with stakeholders?
  • Is there an opportunity to leverage standardization in order to reduce or eliminate the need for redundancy and duplication?
  • Is there potential for leveraging corporate standards or guidelines and supplier standardization?

The project plan should consider task ownership so that there are clear expectations of who will deliver what and when. Although this consideration is universally applicable to all elements of the project, the bottom line is that the delivery of the system, including all software, hardware, documentation, and on-going support and maintenance, must be well understood and agreed upon in writing.

Click to view larger image

Test, And Test Again:

As with any complex project, there will be a lot of trial and error, potentially resulting in rejects and rework. This is primarily because now we are aggregating serial numbers into containers holding smaller serialized units. When the serial-number “chain” is disrupted for whatever reason, the human business processes’ and automated systems’ capabilities to cope with the management of such an issue is key.

Although there are a number of potential scenarios that will inevitably occur, the following is an example based on a standard high-speed packaging operation of between 100 to 200 bottles per minute:

Assumptions:

All labeling within the batch must be uniquely serialized, verified, authenticated, and aggregated during the packaging operation.
At a minimum, the following automated systems, including mechanized ejection capability, are parts of the packaging train: 
(1) controlled creation and issuance of a pool of uniquely serialized values for the specific packaging operation; 
(2) confirmation and verification following application that the bar code is machine readable and is an issued value from the approved pool; 
(3) aggregation of the serialized product during the final boxout into shipping containers to create the parent–child relationship between the uniquely serialized bar code applied to the shipper case and each uniquely serialized container within the shipper; 
(4) reconciliation of used, destroyed, and remaining values against the issuance for the original pool.
Product, labeling, and packaging materials (e.g. container, closures, corrugated shippers) are issued to a packaging suite.

Inevitably, equipment fails, whether using inkjet, laser, thermal transfer, or some other labeling technology.
Upon failure, defective units result, causing rejects that are automatically detected and separated from the rest of the batch.

Depending on product value, rejects are placed in a secured location and destroyed at the conclusion of the batch, or rejects are fully reworked using an approved rework process that specifically addresses the final disposition of the serialized labeled primary container.

As the rejects contain controlled serialized values created for the specific batching operation, these units must be closely controlled and reconciled during the batch-approval process. Discrepancies will result in delayed batch release, potential quarantines, and investigations.

It is evident that any fault in the data linkage will result in significant lost production time. Moreover, considering throughput on today’s high-speed packaging lines, a failure scenario such as the one described above could have significant cost and/or compliance impact.

Internal Corporate Requirements:

Of course, not all of the system requirements will be gleaned from a review of the regulations. So, in addition to the user requirements focused specifically on meeting the regulations, additional requirements will need to be gathered and documented clearly describing our internal users’ expectations for the delivered system. Examples of requirements for this group may read similar to these:

“The system shall be able to monitor availability of serial numbers and notify an operator when a ‘low level’ limit is reached.”

“The system must be able to ‘read’ all serial numbers applied by scanning with appropriate equipment and immediately reject defective units and notify operator(s) when illegible serial number(s) is/are encountered.”
Although the expectations from legislators, regulators, and standards regarding track and trace of pharmaceutical product are being communicated to the industry, it is quickly becoming evident that there are resource limitations throughout the industry to address these new expectations. Attention must now be focused on the extended project piloting and implementation time requirements to get these systems up and running in an accelerated fashion.

At this point, you must implement an aggressive time line to meet the minimum compliance requirements of the California ePedigree Law. I have included one project plan approach, focused on fulfilling the basic requirements. Adherence to the plan does not guarantee a successful implementation, as there are a myriad of variables; however, failure to establish a plan at this late stage certainly guarantees the inability to effectively comply.

ISO 11011: Standardizing Energy Audits

ISO 11011:2013 aims to standardize the energy audit process by establishing guidelines for assessing compressed air leaks. It also addresses the competency of the assessor and the methodologies employed.
 For more than a decade, money wasted through compressed air leaks has often been cited as the number one quick fix manufacturers can take to begin getting a hold on their energy costs. Going back to 1998, a Department of Energy “Compressed Air Challenge” fact sheet notes that “leaks can be a significant source of wasted energy in an industrial compressed air system, sometimes wasting 20-30 percent of a compressor’s output. A typical plant that has not been well maintained will likely have a leak rate equal to 20 percent of total compressed air production capacity.”

Adjusting data from that 1998 Department of Energy fact sheet to 2013 dollars, a 1/4-in. leak that cost $8,382/year in 1998 would now cost a manufacturer $12,026/year. And that’s not even adjusting for the average kWh rate, which was 5 cents/kWh in 1998 and now averages about ~12 cents/kWh.

The bottom line today is the same as it was in 1998: By simply fixing compressed air leaks in your facility, the impact to your bottom is significant. The real question is: Why is this still an issue today?

Prior to ISO 11011, virtually anybody could offer to provide energy surveys, air audits and data logging of compressed air usage, to no recognized standard, with wildly varying results and findings.
 One possible reason is the lack of standardization around the energy audit process in general and dealing with compressed air leaks, specifically.

In October 2013, ECOskills, an environmental training group based in the U.K., held an event to highlight the new ISO 11011:2013 standard to improve compressed air energy assessments.

Speaking at the event, Stephen Boults, capital equipment manager at Thorite (an independent U.K.-based distributor of compressed air products and process systems), explained that over 10 percent of electricity consumed by British industry is used to generate compressed air, yet many unmanaged systems waste 30-40 percent of the compressed air produced.

“Reducing current energy costs is the main driver for instigating an energy efficiency assessment,” said Boults. “Yet, up to now, virtually anybody could offer to provide energy surveys, air audits and data logging of compressed air usage, to no recognized standard, with wildly varying results and findings.”

By establishing requirements on how to conduct an energy efficiency assessment, ISO 11011 is expected to dramatically change the energy audit process. The standard addresses three aspects of compressed air systems: supply, transmission, and demand.

Boults noted that the standard also covers analysis of the assessment data, how the findings are documented, and how estimates of energy savings can be achieved. The standard also addresses the competency of the assessor as well as the assessment methodology, objectives, and scope of the audit.

“ISO 11011 enables industry to receive accurate assessments of the savings achievable by professional management of compressed air systems and the installation of energy-efficient compressors and controllers,” Boults said. “It's a win-win situation for those companies that implement ISO 11011's new energy efficiency assessments, as less electrical power consumption not only saves money but also cuts carbon emissions too.”